Here, we present an updated and larger data set and extend the analysis beyond EGFR and ALK.<h4>Methods</h4>A retrospective review of patients with metastatic NSCLC harboring <i>EGFR/BRAF</i> V600E mutations, or <i>ALK/ROS1/RET</i> rearrangements, who had OPD on respective tyrosine-kinase inhibitor (TKI) and treated with LT was performed. This evidence concerns the gene ALK and non-small cell lung carcinoma.